ARQT Insider Trading Activity and SEC Form 4 Filings
ARQT insider trading summary
Over the past 12 months, insiders at Arcutis Biotherapeutics, Inc. (ARQT) reported 57 sales worth $13.1M by 11 insiders and no open-market purchases on SEC Form 4. Net insider selling was $13.1M.
Latest ARQT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 4, 2026 | Masaru Matsuda | EVP, Chief Legal Officer | Sell | $1.4M (40,000 @ $34.32) |
| Nov 2, 2026 | Masaru Matsuda | EVP, Chief Legal Officer | Sell | $39K (1,219 @ $31.86) |
| Nov 2, 2026 | Todd Watanabe | See Remarks | Sell | $139K (4,377 @ $31.86) |
| Nov 2, 2026 | Patrick Burnett | EVP, Chief Medical Officer | Sell | $30K (943 @ $31.86) |
| Oct 15, 2026 | Howard G. Welgus | Director | Sell | $127K (4,728 @ $26.93) |
| Sep 16, 2026 | Masaru Matsuda | See Remarks | Sell | $92K (3,674 @ $25.00) |
| Sep 15, 2026 | Howard G. Welgus | Director | Sell | $114K (4,730 @ $24.18) |
| Aug 27, 2026 | Terrie Curran | Director | Sell | $677K (27,052 @ $25.03) |
| Aug 27, 2026 | Terrie Curran | Director | Sell | $279K (11,148 @ $25.03) |
| Aug 20, 2026 | Terrie Curran | Director | Sell | $28K (1,072 @ $26.04) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.